Financials

News Discussions Technicals Seasonals

130A fundamentals

Overview Statements Statistics Dividends Earnings Revenue

Key facts

—

—

—

—

—

—

—

—

About

Veritas In Silico Inc. engages in the development of molecular medicine drugs. It provides a platform business for the discovery of mRNA-targeted small molecule and antisense oligonucleotide drugs. The company was founded by Shingo Nakamura on November 17, 2016 and is headquartered in Tokyo, Japan.

Valuation

Fundamental metrics to determine fair value of the stock

Summary

No data available

There's currently no market capitalization, revenue or net income data to show.

Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

No dividends

130A has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company